Page 270 - Read Online

Burns et al. Altered filamin A enables Aβ signaling

and related technology. Ehrlich M. Days-to-criterion as an indicator of toxicity associated with
human Alzheimer amyloid-β oligomers. Ann Neurol 2010;68:220-30.
Patient consent 18. Stancu I-C, Vasconcelos B, Terwel D, Dewachter I. Models of
β-amyloid induced Tau-pathology: the long and “folded” road to
Not applicable. understand the mechanism. Mol Neurodegen 2014;9:51.
19. Medeiros R, Castello N, Cheng D, Kitazawa M, Baglietto-Vargas D,
Ethics approval Green K, Esbenshade T, Bitner R, Decker M, LaFerla F. α7 Nicotinic
Not applicable. receptor agonist enhances cognition in aged 3xTg-AD mice with robust
plaques and tangles. Am J Pathol 2014;184:520-9.
20. Inestrosa N, Godoy J, Vargas J, Arrazola M, Rios J, Carvajal F,
REFERENCES Serrano F, Farias G. Nicotine prevents synaptic impairment induced
by amyloid-β oligomers through α7-nicotinic acetylcholine receptor
activation. Neuromolecular Med 2013;15:549-69.
1. Frost B, Diamond M. Prion-like mechanisms in neurodegenerative 21. Dziewczapolski G, Glogowski C, Masliah E, Heinemann S. Deletion
diseases. Nat Rev Neurosci 2010;11:155-9. of the alpha 7 nicotinic acetylcholine receptor gene improves cognitive
2. Sengupta U, Nilson A, Kayed R. The role of amyloid-β oligomers in deficits and synaptic pathology in a mouse model of Alzheimer’s
toxicity, propagation, and immunotherapy. EBioMedicine 2016;6:42-9. disease. J Neurosci 2009;29:8805-15.
3. Yin R, Tan L, Jiang T, Yu J. Prion-like mechanisms in Alzheimer’s 22. Ni R, Marutle A, Nordberg A. Modulation of α7 nicotinic acetylcholine
disease. Curr Alzheimer Res 2014;11:755-64. receptor and fibrillar amyloid-β interactions in Alzheimer’s disease
4. Eisenberg D, Jucker M. The amyloid state of proteins in human brain. J Alzheimers Dis 2013;33:841-51.
diseases. Cell 2012;148:1188-203. 23. Ondrejcak T, Wang Q, Kew J, Virley D, Upton N, Anwyl R, Rowan M.
5. Rasmussen J, Jucker M, Walkerd L. Ab seeds and prions: how close Activation of α7 nicotinic acetylcholine receptors persistently enhances
the fit? Prion 2017;11:215-25. hippocampal synaptic transmission and prevents Ab-mediated inhibition
6. Nelson R, Sawaya M, Balbirnie M, Madsen A, Riekel C, Grothe R, of LTP in the rat hippocampus. Eur J Pharmacol 2012;677:63-70.
Eisenberg D. Structure of the cross-beta spine of amyloid-like fibrils. 24. D’Andrea M, Nagele R. Targeting the alpha 7 nicotinic acetylcholine
Nature 2005;435:773-8. receptor to reduce amyloid accumulation in Alzheimer’s disease
7. Alonso A, Zaidi T, Grundke-Iqbal I, Iqbal K. Role of abnormally pyramidal neurons. Curr Pharm Des 2006;12:677-84.
phosphorylated tau in the breakdown of microtubules in Alzheimer 25. Tong M, Arora K, White M, Nichols R. Role of key aromatic residues
disease. PNAS 1994;91:5562-6. in the ligand-binding domain of alpha7 nicotinic receptors in the
8. Friedhoff P, von Bergena M, Mandelkowa EM, Mandelkow E. agonist action of beta-amyloid. J Biol Chem 2011;286:34373-81.
Structure of tau protein and assembly into paired helical filaments. 26. Wang H, Lee D, Davis C, Shank R. Amyloid peptide Abeta(1-42) binds
selectively and with picomolar affinity to alpha7 nicotinic acetylcholine
Biochimica et Biophysica Acta 2000;1502:122-32.
receptors. J Neurochem 2000;75:1155-61.
9. Alonso A, Grundke-Iqbal I, Barra H, Iqbal K. Abnormal 27. Wang H, Li W, Benedetti N, Lee D. a7 Nicotinic acetylcholine
phosphorylation of tau and the mechanism of Alzheimer neurofibrillary receptors mediate b-amyloid peptide-induced tau protein
degeneration: sequestration of microtubule-associated proteins 1 and phosphorylation. J Biol Chem 2003;278:31547-53.
2 and the disassembly of microtubules by the abnormal tau. PNAS 28. Wang HY LD, D’Andrea MR, Peterson PA, Shank RP, Reitz AB. beta-
1997;94:298-303. Amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with
10. Hoover B, Reed M, Su J, Penrod R, Kotilinek L, Grant M, Pitstick high affinity. Implications for Alzheimer’s disease pathology. J Biol
R, Carlson G, Lanier L, Yuan L, Ashe K, Liao D. Tau mislocalization Chem 2000;275:5626-32.
to dendritic spines mediates synaptic dysfunction independently of 29. Dineley K, Bell K, Bui D, Sweatt J. b-Amyloid peptide activates a7
neurodegeneration. Neuron 2010;68:1067-81. nicotinic acetylcholine receptors expressed in xenopus oocytes. J Biol
11. Ittner L, Ke Y, Delerue F, Bi M, Gladbach A, van Eersel J, Wölfing H, Chem 2002;277:25056-61.
Chieng B, Christie M, Napier I, Eckert A, Staufenbiel M, Hardeman 30. Hu M, Waring J, Gopalakrishnan M, Li J. Role of GSK-3beta activation
E, Götz J. Dendritic function of tau mediates amyloid-beta toxicity in and alpha7 nAChRs in Abeta(1-42)-induced tau phosphorylation in
Alzheimer’s disease mouse models. Cell 2010;142:387-97. PC12 cells. J Neurochem 2008;106:1371-7.
12. Kowall N, Kosik K. Axonal disruption and aberrant localization of tau 31. Zhang L, Xie J, Yang J, Cao Y. Tyrosine phosphatase STEP61
protein characterize the neuropil pathology of Alzheimer’s disease. Ann negatively regulates amyloid β-mediated ERK/CREB signaling
Neurol 1987;22:639-43. pathways via α7 nicotinic acetylcholine receptors. J Neurosci Res
13. Wang HY, Lee KC, Pei Z, Khan A, Bakshi K, Burns L. PTI-125 2013;91:1581-90.
binds and reverses an altered conformation of filamin A to reduce 32. Wang HY, Li W, Benedetti N, Lee D. α7 nicotinic acetylcholine
Alzheimer’s disease pathogenesis. Neurobiol Aging 2017;55:99-114. receptors mediate β-amyloid peptide-induced tau protein
phosphorylation. J Biol Chem 2003;278:31547-53.
14. Gambuzza M, Sofo V, Salmeri F, Soraci L, Marino S, Bramanti P. Toll- 33. Dineley K, Bell K, Bui D, Sweatt J. b-Amyloid peptide activates a7
like receptors in Alzheimer’s disease: a therapeutic perspective. CNS nicotinic acetylcholine receptors expressed in xenopus oocytes. J Biol
Neurol Disord Drug Targets 2014;13:1542-58. Chem 2002;227:25056-61.
15. Wang H-Y, Bakshi K, Frankfurt M, Stucky A, Goberdhan M, Shah S, 34. Wang HY, Bakshi K, Shen C, Frankfurt M, Trocme-Thibierge C,
Burns L. Reducing amyloid-related Alzheimer’s disease pathogenesis Morain P. S 24795 limits b-amyloid - a7 nicotinic receptor interaction
by a small molecule targeting filamin A. J Neurosci 2012;32:9773-84. and reduces Alzheimer’s disease-like pathologies. Biol Psychiatry
16. Näslund J, Haroutunian V, Mohs R, Davis K, Davies P, Greengard 2010;67:522-30.
P, Buxbaum J. Corrleation between elevated levels of amyolid beta- 35. Wang HY, Stucky A, Liu J, Shen C, Trocme-Thibierge C, Morain P.
peptide in the brain and cognitive decline. JAMA 2000;283:1571-7. Dissociating beta-amyloid from alpha 7 nicotinic acetylcholine receptor
17. Gandy S, Simon A, Steele J, Lublin A, Lah J, Walker L, Levey A, by a novel therapeutic agent, S 24795, normalizes alpha 7 nicotinic
Krafft G, Levy E, Checler F, Glabe C, Bilker W, Abel T, Schmeidler J, acetylcholine and NMDA receptor function in Alzheimer’s disease
270 Neuroimmunology and Neuroinflammation ¦ Volume 4 ¦ December 8, 2017